Please assess the completion status of the following clinical trial:

Trial Title: Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or above~* Written informed consent from the trial subject has been obtained~* Willing to follow contraception guidelines~* Tested positive for SARS-CoV-2 by PCR \<72 hours after swab~* A maximum of 14 days between onset of symptoms and enrollment~* WHO score 5 OR~* WHO score 4 with at least one additional risk factor for disease progression~* Acceptable risk factors are:~  * Radiographically proven lung infiltrates~ * Immunosuppression either by malignant disease or it's treatment, or other underlying diseases leading to immunodeficiency or underlying diseases that require treatment resulting in immunosuppression~ * Immunosuppressive drugs or steroids at a prednisolone equivalent of \<1 mg/kg BW)~ * Receipt of an autologous transplant within the last 5 years~ * Receipt of an allogeneic transplant within the last 5 years or ongoing immunosuppression~Exclusion criteria:~* Participation in any other clinical trial of an experimental agent treatment~* Active GvHD or history of GvHD~* History of CAR-T-Cell Therapy~* COVID-19 WHO ordinal scale ≥6~* Anticipated life-expectancy \<72 hours~* Expected duration of hospital stay \<72 hours~* Sepsis-induced leukopenia or thrombocytopenia (leukocytes \<1,000/µl or platelets \<50,000/µl). If the cytopenias result from underlying hematologic disease or its treatment this will not be regarded as exclusion criterion~* CT pneumonia score ≥13 \[50\]~* Any Steroids ≥1 mg/kg Prednisolon-equivalent/kg BW, besides 6 mg Dexamethasone i.v. or p.o. 1x/d as SoC for COVID-19~* Pregnant or breast feeding~* Any serious medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the subject's safe participation in and completion of the study~* Therapeutic donor lymphocyte infusion (DLI) less than 100 days prior to IMP infusion~* Known hypersensitivity to iron dextran~* Known pre-existing human anti-mouse antibodies (HAMAs)~* ontraindication against mandatory protocol-inherent comedication(s): antihistamine and/or acetaminophen~* Failure to use highly-effective contraceptive methods. The following contraceptive methods with a Pearl Index lower than 1% are regarded as highly-effective:~  * Oral hormonal contraception ('pill')~ * Dermal hormonal contraception~ * Vaginal hormonal contraception (NuvaRing®)~ * Contraceptive plaster~ * Long-acting injectable contraceptives~ * Implants that release progesterone (Implanon®)~ * Tubal ligation (female sterilization)~ * Intrauterine devices that release hormones (hormone spiral)~ * Double barrier methods~ * This means that the following are not regarded as safe: condom plus spermicide, simple barrier methods (vaginal pessaries, condom, female condoms), copper spirals, the rhythm method, basal temperature method, and the withdrawal method (coitus interruptus).~* Persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator~* Legally incapacitated persons~* Persons held in an institution by legal or official order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Dose escalation (Type: EXPERIMENTAL): SARS CoV-2 infected participants will receive a single infusion over 15 to 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues